Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
Zaragozic acid A trisodium salt has been used as: a component of serum-free medium for human embryonic kidney cells in a wound scratch assay to test its effect on wound healinga farnesyl-diphosphate farnesyltransferase 1 (FDFT1) or squalene synthase inhibitor in stromal cells a cholesterol synthesis inhibitor in T cells
Biochem/physiol Actions
Potent inhibitor, in vivo and in vitro, of mammalian, fungal and Saccharomyces cervisiae squalene synthase. Squalene synthase is the first committed enzyme in sterol synthesis, catalyzing the reductive condensation of farnesyl pyrophosphate to form squalene. As a squalene synthase inhibitor, zaragozic acid produces lower plasma cholesterol levels in primates. Treatment of rats with zaragozic acid A caused an increase in hepatic low density lipoprotein (LDL) receptor mRNA levels.
Legal Information
Manufactured and sold under a restricted license from Merck & Co., Inc., Kenilworth, NJ, U.S.
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :